Can a targeted drug stall lymphoma before it starts?
NCT ID NCT03282396
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests the drug ibrutinib in 20 people with untreated, high-risk smoldering mantle cell lymphoma (MCL), a slow-growing blood cancer. The goal is to see if ibrutinib can stop the cancer from progressing by blocking enzymes that help cancer cells grow. Participants have not received any prior treatment and are monitored for safety and how long they stay cancer-free.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ibrutinib (a targeted cancer drug that blocks enzymes needed for cell growth)
What this could lead to
If successful, this could point toward a way to delay or prevent active lymphoma in people with early-stage, high-risk disease.
What could go wrong
This is a small, early-phase trial with only 20 participants, so results may not apply broadly. Side effects from ibrutinib are possible, and it is not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States